NanoViricides, Inc. (NNVC) is a pioneering global pharmaceutical company that specializes in the discovery, research, and development of potent therapeutic agents called nanoviricides. They use their advanced, proprietary technology to target life-threatening viral infections. The company's name is derived from "nano", referring to the nanotechnology-based approach it applies and "viricides", which signifies the company's main focus on developing therapeutic solutions to combat various viral diseases.
Founded in 2005 and with headquarters based in Shelton, Connecticut, USA, NanoViricides is highly regarded as a leader in nanomedicine. This groundbreaking company became publicly listed as NNVC on the NYSE American in 2013.
The company's core business strategy revolves around the development of highly targeted drugs that can directly attack and dismantle infectious viruses. Using nanomedicine, the company engenders "nanomachine" substances that are programmed to recognize the markers of specific viruses, and then incapacitate them, preventing their spread.
NanoViricides, Inc. is responsible for the discovery and investigation of a patented class of drugs known as "nanoviricides". These so-called virus-killing nano-drugs are designed to mimic the natural targets that viruses bind to or enter during infection. They envelop the virus, like a "Venus flytrap", and disrupt its lifecycle.
One of the most notable developments from NanoViricides is its experimental drug candidate for the treatment of the shingles virus, also known as Herpes Zoster. Furthermore, the company has been researching potential treatments for Covid-19. Beyond these projects, NanoViricides also has drug candidates against major diseases such as HIV, Influenza, and Herpes.
Overall, NanoViricides strives to develop new approaches to therapeutic solutions in virology with its use of innovative technology to combat viral diseases. Backed by a team of experts in the field of nanomedicine, virology, and molecular drug development, the company is at the frontline of the war against dangerous viral infections.
Despite facing intense competition from bigger pharmaceutical giants, NanoViricides, Inc. remains focused on its path. The company's continuous dedication to innovation and exploration in the domain of virology is setting new horizons, thereby making it a significant player in the healthcare industry.